•  
  •  
  •  
  •  

2026-07-20 11:34:33

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • JioStar Reports Strong Q1 FY27 Performance: EBITDA Operations Up 30.7% as JioHotstar Hits Record 530 Million MAUs
  • Reliance Retail Ventures Limited Reports Q1 FY27 Gross Revenue of ₹90,408 Crore: Digital Commerce Surges Across Consumption Baskets
  • Jio Platforms Reports Surge in Q1 FY27 Net Profit to ₹7,764 Crore: EBITDA Margins Expand to Record 53.3%
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality

Keywords Selected:  Tablets

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Lupin Launches Azilsartan Medoxomil Tablets in the United States
  • Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg
  • Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Unichem Pharmaceuticals (USA) Issues Voluntary Recall of Buspirone Hydrochloride Tablets
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg
  • Eugia Pharma receives USFDA Approval for Everolimus Tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg

Latest Post

  • JioStar Reports Strong Q1 FY27 Performance: EBITDA Operations Up 30.7% as JioHotstar Hits Record 530 Million MAUs
  • Reliance Retail Ventures Limited Reports Q1 FY27 Gross Revenue of ₹90,408 Crore: Digital Commerce Surges Across Consumption Baskets
  • Jio Platforms Reports Surge in Q1 FY27 Net Profit to ₹7,764 Crore: EBITDA Margins Expand to Record 53.3%
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025